Compounds > fludarabine

fludarabine and Local Neoplasm Recurrence

fludarabine has been researched along with Local Neoplasm Recurrence in 96 studies

Research

Studies (96)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (4.17)18.2507
2000's32 (33.33)29.6817
2010's36 (37.50)24.3611
2020's24 (25.00)2.80

Authors

AuthorsStudies
Appelbaum, FR; Cooper, JP; Deeg, HJ; Doney, K; Flowers, MED; Gooley, T; Martin, PJ; McCune, JS; McFarland, C; O'Donnell, PV; Schoch, G; Sorror, ML; Storer, BE; Yeh, AC1
Atsuta, Y; Fukuda, T; Imada, K; Ishiyama, K; Itonaga, H; Kako, S; Kanda, J; Kanda, Y; Kawakita, T; Kimura, T; Kobayashi, T; Kurosawa, S; Maruyama, Y; Matsuoka, KI; Najima, Y; Nakazawa, H; Ota, S; Ozawa, Y; Shimomura, Y1
Bassermann, F; Braitsch, K; Götze, KS; Herhaus, P; Hubbuch, M; Keller, U; Koch, K; Menzel, H; Schwarz, A; Verbeek, M1
Ali, N; Bal, SK; Boughan, KM; Caimi, PF; Cooper, BW; de Lima, M; de Rezende, ACP; Gallogly, M; Hamerschlak, N; Kerbauy, L; Kerbauy, MN; Latif, BM; Malek, E; Mansur, D; Metheny, L; Otegbeye, F; Pereira, G; Ribeiro, AF; Sakuraba, R; Sanchez, G; Sekaly, RP; Sharma, AA; Tomlinson, BK; Weltman, E1
Afanasyev, B; Beynarovich, A; Borzenkova, E; Kondakova, E; Kozlov, A; Kulagin, A; Lepik, K; Mikhailova, N; Moiseev, I; Pirogova, O; Stelmakh, L; Volkov, N; Zalyalov, Y; Zubarovskaya, L1
Ahmed, S; Alousi, A; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Hosing, C; Kawedia, J; Kebriaei, P; Kornblau, S; Ma, J; Myers, A; Nieto, Y; Oran, B; Parmar, S; Popat, UR; Rezvani, K; Shah, N; Shpall, E; Thall, PF; Valdez, BC1
Artz, AS; Aydogan, B; Bishop, MR; Hasan, Y; Kline, J; Kosuri, S; LaBelle, JL; Larson, RA; Liu, H; Partouche, J; Riedell, PA; Stock, W; Tran, MC; Wang, A; Weichselbaum, R; Yenice, K1
Bertz, H; Bornhäuser, M; Burchert, A; Dreger, P; Finke, J; Glass, B; Grishina, O; Hegenbart, U; Kobbe, G; Reicherts, C; Schmoor, C; Schub, N; Sohlbach, K; Stelljes, M; Wagner-Drouet, EM1
Fu, Y; Gui, R; Guo, S; Li, Z; Song, Y; Wang, X; Zhan, X; Zhang, B; Zhang, W; Zhang, Y; Zhou, J; Zu, Y1
Baek, S; Bong, CE; Choi, EJ; Choi, Y; Jeon, M; Kang, H; Kang, YA; Kim, SM; Lee, JH; Lee, KH; Lee, YS; Park, HS; Woo, JM1
Ara, T; Ashida, T; Atsuta, Y; Fukuda, T; Kamijo, K; Kanaya, M; Kim, SW; Kondo, E; Kuriyama, T; Kusumoto, S; Maseki, N; Matsuoka, KI; Mizuno, I; Mizuno, S; Nakazawa, H; Onizuka, M; Shimomura, Y; Shinohara, A; Usui, Y; Yamaguchi, M1
Beasley, M; Castleton, A; Chakraverty, R; Diez, P; Elhanied, M; Fielding, A; Gilleece, M; Hodgkinson, A; Jackson, A; Marks, DI; Mikhaeel, G; Olavarria, E1
Shimoni, A1
Jayakumar, I; Patel, S; Raj, R; Ramakrishnan, B; Ramanan, KM; Ravichandran, N; Swaminathan, VV; Uppuluri, R1
Ahn, KW; Awan, FT; Chow, VA; Eghtedar, A; Fenske, TS; Hamadani, M; Karmali, R; Khanal, M; Kharfan-Dabaja, MA; Litovich, C; Sauter, C; Winter, A1
Bertrand, Y; Girard, S; Marceau-Renaut, A; Penel-Page, M; Plesa, A; Renard, C1
Daly, A; Dharmani-Khan, P; Duggan, PR; Jamani, K; Jimenez-Zepeda, V; Kalra, A; Khan, FM; Ousia, S; Prokopishyn, N; Russell, JA; Storek, J; Williamson, TS1
Slater, H1
Adachi, S; Goto, H; Hasegawa, D; Iwamoto, S; Kakuda, H; Koh, K; Miyamura, T; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D; Yuza, Y1
Cui, Q; Hu, Y; Huang, H; Liang, Z; Shao, M; Wu, Z; Xiao, L; Zhang, H1
Brammer, JE; Choe, H; Dickerson, T; Elder, P; Jaglowski, S; Larkin, K; Mims, A; Penza, S; Puto, M; Rasor, B; Roddy, JVF; Saad, A; Vasu, S; Wall, SA; William, B; Zhao, Q1
Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M1
Allsup, D; Baird, DM; Bomben, R; Bulian, P; Catovsky, D; Fegan, CD; Gattei, V; Hillmen, P; Hockaday, A; Norris, K; Ow, PL; Pepper, AGS; Pepper, C; Polesel, J; Rawstron, A; Soe, Z; Tissino, E; Zucchetto, A1
Cai, QQ; Cao, JN; Feng, JF; Gao, Y; Huang, HQ; Jiang, WQ; Jin, J; Li, ZM; Wang, HQ; Wang, XX; Zhang, HL1
Borthakur, G; Brandt, M; Cortes, JE; Daver, NG; DiNardo, CD; Estrov, Z; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Konopleva, M; O'Brien, SM; Pemmaraju, N; Plunkett, W; Ravandi, F; Sasaki, K; Short, NJ; Wierda, WG; Xiao, L1
Blumenthal, GM; Bouchkouj, N; Bryan, W; de Claro, RA; George, B; Kasamon, YL; Lee, S; Lin, X; McKee, AE; Pazdur, R1
Aiyer, HM; Bansal, S; Bhakuni, P; Bhargava, S; Chakrabarti, S; Jaiswal, SR1
Bühler, A; Busch, R; Cazzola, M; Döhner, H; Döhner, K; Edelmann, J; Hallek, M; Kless, S; Mack, S; Mertens, D; Paschka, P; Rossi, M; Schnaiter, A; Stilgenbauer, S; Winkler, D; Zenz, T1
Cartron, G; Davies, A; Lei, G; Marcus, R; Morschhauser, F; Radford, J; Salles, G; Vitolo, U; Wassner-Fritsch, E; Wenger, M1
Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X1
Barth, MJ; Czuczman, MS1
Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N1
Campos, JG; Carrillo-Cruz, E; Cuadrado, IM; De la Cruz Vicente, F; Galiana, ML; Gonzalez, JF; Marín Niebla, A; Perez-Simón, JA; Rios-Herranz, E; Rodriguez, MS; Tocino, IE1
Argnani, L; Broccoli, A; Casadei, B; Gandolfi, L; Maglie, R; Pellegrini, C; Pileri, S; Stefoni, V; Zinzani, PL1
Cox, EA; Cripe, LD; Farag, SS; Khawaja, MR; Kiel, PJ; Nelson, RP; Perkins, SM; Robertson, MJ; Sayar, H; Schwartz, JE; Vance, GH1
Asselineau, J; Blaise, D; Bouabdallah, K; Bouabdallah, R; Ceballos, P; Chevalier, P; Doussau, A; Furst, S; Le Gouill, S; Milpied, N; Mohty, M; Tabrizi, R; Tournilhac, O; Vigouroux, S1
Afanasyev, B; Baron, F; Deconinck, E; Jindra, P; Labopin, M; Mohty, M; Nagler, A; Peniket, A; Sanz, MA1
Adachi, S; Atsuta, Y; Goto, H; Hasegawa, D; Inagaki, J; Inoue, M; Ishida, H; Kato, K; Kawa, K; Koh, K; Kudo, K; Okamoto, Y; Yabe, H1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Yoon, JH1
Aulitzky, W; Bornhäuser, M; Ehninger, G; Fiedler, F; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Lange, T; Maschmeyer, G; Morgner, A; Neugebauer, S; Niederwieser, D; Peter, N; Pönisch, W; Schäfer-Eckart, K; Schetelig, J; Schulze, A; Thiel, A; Wilhelm, M1
Anacak, Y; Aydinok, Y; Balkan, C; Delcastello, BE; Kamer, SA; Karadaş, N; Karapinar, DY; Kavakli, K1
Bucur, S; Cohen, JB; Colbert, A; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; King, N; Langston, AA; Lechowicz, MJ; Lonial, S; Sinha, R; Waller, EK; Winton, EF1
Al-Ali, HK; Behre, G; Franke, GN; Hochhaus, A; Jentzsch, M; Klink, A; Niederwieser, D; Pfrepper, C; Sayer, HG; Schenk, T; Schwind, S1
Alyea, EP; Blum, W; Carter, S; Champlin, RE; Chen, YB; Devine, SM; Giralt, S; Hars, V; Horowitz, MM; Hsu, JW; Larson, RA; Linker, C; Mulkey, F; Owzar, K; Shea, TC; Sibley, AB; Slack, J; Soiffer, RJ; Stone, RM; Vij, R1
Berrebi, A; Shvidel, L1
Agathangelidis, A; Baliakas, P; Belessi, C; Blakemore, SJ; Chiorazzi, N; Clifford, R; Cortese, D; Davi, F; Gaidano, G; Ghia, P; Höglund, M; Juliusson, G; Kotaskova, J; Langerak, AW; Ljungström, V; Mansouri, L; Ntoufa, S; Oscier, D; Panagiotidis, P; Pandzic, T; Plevova, K; Pospisilova, S; Pott, C; Rosenquist, R; Rossi, D; Schuh, A; Sjöblom, T; Smedby, KE; Stamatopoulos, K; Stavroyianni, N; Strefford, JC; Sutton, LA; Trentin, L; Young, E1
Biemond, BJ; Cornelissen, JJ; Graux, C; Hazenberg, CL; Kuball, J; Löwenberg, B; Maertens, J; Ossenkoppele, G; Pabst, T; Passweg, JR; Schouten, HC; Theobald, M; van Putten, WL; Vellenga, E; Versluis, J1
Cao, J; Reilly, JZ; Rodmyre, RM; Thompson, JA; Wallen, H; Yee, C1
Ando, K; Hayashi, M; Hotta, T; Ishizawa, K; Itoh, K; Matsusako, M; Morishima, Y; Nakata, M; Nawano, S; Ogura, M; Taniwaki, M; Terauchi, T; Tobinai, K; Uchida, T; Watanabe, T; Yamamoto, J1
Boyd, TE; Chanan-Khan, AA; Gribben, J; Itri, LM; Koziner, B; Larratt, LM; Moore, JO; O'Brien, S; Rai, KR; Seymour, JF; Skotnicki, AB1
Bell, T; Inaba, H; Leung, W; Pounds, S; Pui, CH; Ribeiro, RC; Rooney, B; Rubnitz, JE1
Blanc, A; Corre, J; Fournié, JJ; Gross, E; Kühlein, E; Laurent, G; Quillet-Mary, A; Ysebaert, L1
Cavazzini, F; Ciccone, M; Cuneo, A; De Angeli, C; Ferracin, M; Grilli, A; Lupini, L; Negrini, M; Rizzotto, L; Saccenti, E; Veronese, A; Zagatti, B1
Assisi, D; D'Andrea, M; Dessanti, L; Maini, CL; Petti, MC; Pisani, F; Sciuto, R1
Abdullah, A; Ho, AY; Kenyon, M; Krishnamurthy, P; Lea, N; Lim, ZY; Marsh, J; Mufti, GJ; Nagi, W; Pagliuca, A; Potter, V; Reiff-Zall, L; Tindell, V1
Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H1
Barisone, E; Berger, M; Fagioli, F; Galletto, C; Manicone, R; Masetti, R; Pession, A; Quarello, P; Rivetti, E1
Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M1
Abbenante, MC; Astolfi, A; Baccarani, M; Candoni, A; Cattina, F; Damiani, D; Fanin, R; Ferrari, A; Formica, S; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Lonetti, A; Malagola, M; Martinelli, G; Michelutti, A; Ottaviani, E; Papayannidis, C; Parisi, S; Russo, D; Sazzini, M; Simeone, E1
Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Döhner, H; Elter, T; Engert, A; Fink, AM; Fischer, K; Gassmann, W; Hallek, M; Hasan, I; James, R; Kahl, C; Ritgen, M; Staib, P; Stauch, M; Stilgenbauer, S; Wendtner, CM; Winkler, D1
Kato, J; Kikuchi, T; Kohashi, S; Mori, T; Okamoto, S; Ono, Y; Shimizu, T; Yamane, A1
Bosanquet, AG; Catovsky, D; Else, M; Matutes, E; Richards, SM; Wade, R1
Aivado, M; Burger, J; Finke, J; Haas, R; Henze, L; Schulte, K1
Brand, R; Corradini, P; Deliliers, GL; Dreger, P; Finke, J; Hansz, J; Martino, R; Michallet, M; Milligan, D; Niederwieser, D; Russell, N; Van Biezen, A1
Davis, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Shen, Y; Thomas, MB; Yang, Y1
Andreeff, M; Calvert, LR; Faderl, S; Keating, M; McConkey, DJ; Niemer, I; Pahler, JC; Ruiz, S1
Beyer, J; Claviez, A; Dörffel, W; Dreger, P; Ehninger, G; Klingebiel, T; Nürnberger, W; Schmitz, N; Suttorp, M1
Al-Ali, H; Brand, R; Deininger, M; Gentilini, C; Hegenbart, U; Krahl, R; Lange, T; Leiblein, S; Niederwieser, D; Petersdorf, E; Poenisch, W; Storb, RF; Uharek, L1
Dmoszyńska, A; Hellmann, A; Komarnicki, M; Kowal, M; Kuliczkowski, K; Kłoczko, J; Lewandowski, K; Piszcz, J; Roznowski, K; Skotnicki, AB; Wegrzyn, J; Wołowiec, D1
Byun, JH; Hong, YS; Kim, CC; Lee, JW; Lee, MA; Min, WS; Park, JN; Roh, SY; Shim, BY; Song, CW1
Agura, E; Al-Ali, H; Blume, KG; Bredeson, C; Bruno, B; Chauncey, TR; Hegenbart, U; Langston, A; Leis, J; Loken, MR; Maloney, DG; Maris, MB; McSweeney, P; Pulsipher, M; Radich, JP; Sandmaier, BM; Sorror, ML; Storb, R; Storer, BE; Stuart, MJ1
Benesch, M; Dornbusch, HJ; Lackner, H; Schwinger, W; Sovinz, P; Urban, C1
Boudreaux, CW; Michael, CW; Richardson, PH1
Hirschman, R; Mastan, A; Ng, R; Rashid, K; Sager, D1
Auerbach, AD; Defor, TE; Macmillan, ML; Slungaard, A; Tan, PL; Wagner, JE1
Bao, L; Huang, XJ; Jiang, B; Lu, DP; Lu, J; Lu, XJ; Qiu, JY; Shi, HX; Wang, DB; Wang, FR1
Hong, WD; Li, J; Luo, SK; Tong, XZ; Zhao, Y1
Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ1
Brugiatelli, M; Federico, M; Liberati, M; Marcheselli, R; Merli, F; Orsucci, L; Pozzi, S; Sacchi, S; Tucci, A; Vallisa, D1
Albarello, A; Bacigalupo, A; Balleari, E; Balocco, M; Carella, AM; Catania, G; Clavio, M; Gobbi, M; Manna, A; Michelis, G; Miglino, M; Pierri, I; Sessarego, M; Van Lint, MT; Varaldo, R; Vignolo, L1
Artz, AS; Daugherty, C; Godley, L; Huo, D; Larson, R; Odenike, OM; Pollyea, DA; Rich, E; Smith, SM; Stock, W; van Besien, K; Zhang, Y; Zimmerman, T1
Chen, L; Lü, SQ; Ni, X; Song, XM; Wang, JM; Xu, XQ; Yang, JM; Zhang, WP1
Atanackovic, D; Ayuk, F; Bacher, U; Bethge, W; Bokemeyer, C; Bornhäuser, M; Dierlamm, J; Gutierrez, NC; Hansen, T; Kröger, N; Liebisch, P; Miguel, JS; Nagler, A; Otterstetter, S; Penas, EM; Pérez-Simón, JA; San Miguel, J; Schilling, G; Schwerdtfeger, R; Shimoni, A; Simon-Perez, JA; Zabelina, T; Zander, A1
Amess, J; Ganjoo, RK; Johnson, PW; Lim, J; Lister, TA; Norton, AJ; Pigaditou, A; Rohatiner, AZ; Rossi, A; Whelan, JS1
Bosch, F; Briones, J; Colomer, D; Esteve, J; Hadjieu, E; López-Guillermo, A; Montserrat, E; Rozman, C; Urbano-Ispizua, A1
Aziz, M; Levin, M; Opitz, L1
Nagler, A; Slavin, S1
Belanger, C; François, S; Hermine, O; Lebas de La Cour, JC; Lefrère, F; Tilly, H; Troussard, X; Valensi, F; Varet, B1
Nagler, A; Naparstek, E; Or, R; Samuel, S; Slavin, S; Varadi, G1
Chevret, S; Mahé, C1
Döhner, H; Gabler, A; Haas, R; Hartmann, F; Hensel, M; Ho, AD; Jung, W; Schlenk, RF; Trümper, L; Weber-Nordt, R1
Albitar, M; Binet, JL; Brettman, L; Byrd, J; Flinn, I; Hillmen, P; Jain, V; Keating, MJ; Rai, KR; Santabarbara, P; Wacker, B1
Clausen, NT; Hansen, PB; Larsen, CR1
Kasznicki, M; Robak, T1
Barlogie, B; Desikan, KR; Dhodapkar, MV1

Reviews

6 review(s) available for fludarabine and Local Neoplasm Recurrence

ArticleYear
Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?
    Expert review of hematology, 2016, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Prognosis; Rituximab; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine

2016
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Leukemia, 2003, Volume: 17, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2003
Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Safety; Survival Rate; Treatment Outcome; Vidarabine

2004
Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9 Suppl 1

    Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Combined Modality Therapy; Cytokines; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunotherapy, Adoptive; Interleukin-2; Lymphoma; Neoplasm Recurrence, Local; Neoplasm, Residual; Recombinant Proteins; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine

1998
Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
    Leukemia, 2002, Volume: 16, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Nucleosides; Survival Rate; Treatment Failure; Vidarabine

2002
Waldenström's macroglobulinemia.
    Current treatment options in oncology, 2000, Volume: 1, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; beta 2-Microglobulin; Chlorambucil; Cladribine; Clinical Trials as Topic; Combined Modality Therapy; Humans; Interferon-alpha; Neoplasm Recurrence, Local; Plasmapheresis; Rituximab; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia

2000

Trials

31 trial(s) available for fludarabine and Local Neoplasm Recurrence

ArticleYear
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:7

    Topics: Adolescent; Adult; Aged; Bone Marrow; Busulfan; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine

2022
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.
    Bone marrow transplantation, 2022, Volume: 57, Issue:8

    Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Transplantation Conditioning; Vidarabine

2022
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
    Blood advances, 2023, 02-14, Volume: 7, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Neoplasm Recurrence, Local

2023
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
    Bone marrow transplantation, 2022, Volume: 57, Issue:11

    Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine

2022
Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A
    British journal of haematology, 2023, Volume: 200, Issue:2

    Topics: Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning

2023
ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.
    BMJ open, 2023, 06-01, Volume: 13, Issue:6

    Topics: Acute Disease; Adult; Alemtuzumab; Clinical Trials, Phase II as Topic; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Whole-Body Irradiation

2023
Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Vidarabine

2020
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 09-01, Volume: 39, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Sulfonamides; Survival Rate; Vidarabine; Young Adult

2021
Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.
    Annals of hematology, 2021, Volume: 100, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Female; Humans; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Vidarabine

2021
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2018
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 03-15, Volume: 25, Issue:6

    Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modality Therapy; Cyclophosphamide; Drug Approval; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Leukapheresis; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration; Vidarabine; Young Adult

2019
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
    Blood, 2013, Aug-15, Volume: 122, Issue:7

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Phosphoproteins; Prognosis; Prospective Studies; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Survival Rate; Tumor Suppressor Protein p53; Vidarabine

2013
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
    Blood, 2013, Aug-15, Volume: 122, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Prognosis; Vidarabine; Vincristine

2013
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:1

    Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2015
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Vidarabine; Young Adult

2015
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Rituximab; Vidarabine

2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-10, Volume: 33, Issue:35

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2015
Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
    PloS one, 2009, Volume: 4, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cytokines; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Forkhead Transcription Factors; Humans; Immunotherapy, Adoptive; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome; Vidarabine

2009
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
    Cancer science, 2009, Volume: 100, Issue:10

    Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine

2009
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-01, Volume: 27, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Thionucleotides; Vidarabine

2009
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.
    Molecular cancer, 2010, May-26, Volume: 9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Vidarabine

2010
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
    Haematologica, 2012, Volume: 97, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Pilot Projects; Prognosis; Prospective Studies; Remission Induction; Rituximab; Sex Factors; Survival Rate; Tissue Distribution; Vidarabine

2012
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
    Leukemia, 2012, Volume: 26, Issue:12

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Vidarabine

2012
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Bone marrow transplantation, 2007, Volume: 39, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladribine; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2007
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
    Cancer, 2007, Jul-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gene Rearrangement; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thrombocytopenia; Time Factors; Treatment Outcome; Vidarabine

2007
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison
    British journal of haematology, 2007, Volume: 138, Issue:2

    Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome; Vidarabine

2007
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
    Bone marrow transplantation, 2007, Volume: 40, Issue:11

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine

2007
Fludarabine in low-grade lymphoma.
    Seminars in oncology, 1993, Volume: 20, Issue:5 Suppl 7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Vidarabine

1993
[Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
    Medicina clinica, 1996, Jun-15, Volume: 107, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Vidarabine

1996
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
    Leukemia, 2002, Volume: 16, Issue:4

    Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
    Blood, 2002, May-15, Volume: 99, Issue:10

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Demography; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine

2002

Other Studies

59 other study(ies) available for fludarabine and Local Neoplasm Recurrence

ArticleYear
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.
    Bone marrow transplantation, 2022, Volume: 57, Issue:2

    Topics: Antilymphocyte Serum; Busulfan; Chimerism; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation Conditioning; Vidarabine

2022
Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:6

    Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Propensity Score; Retrospective Studies; Vidarabine

2022
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
    Annals of hematology, 2022, Volume: 101, Issue:6

    Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Vidarabine

2022
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
    International journal of hematology, 2022, Volume: 116, Issue:3

    Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2022
A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study.
    British journal of haematology, 2023, Volume: 200, Issue:5

    Topics: Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Prospective Studies; Siblings; Transplantation Conditioning; Unrelated Donors

2023
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
    Annals of hematology, 2023, Volume: 102, Issue:3

    Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Transplantation Conditioning; Vidarabine

2023
Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity.
    The Lancet. Haematology, 2020, Volume: 7, Issue:1

    Topics: Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine

2020
FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria.
    Journal of pediatric hematology/oncology, 2021, 03-01, Volume: 43, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Child, Preschool; Cytarabine; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Vidarabine

2021
Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:6

    Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2020
Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin.
    Clinical transplantation, 2020, Volume: 34, Issue:9

    Topics: Aged; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myeloablative Agonists; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2020
Interim Phase 2 ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL.
    Oncology (Williston Park, N.Y.), 2020, Jul-15, Volume: 34, Issue:7

    Topics: Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Immunotherapy, Adoptive; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Salvage Therapy; Vidarabine

2020
The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:1

    Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Transplantation, Homologous; Vidarabine

2021
Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report.
    Medicine, 2020, Oct-23, Volume: 99, Issue:43

    Topics: Adult; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytokine Release Syndrome; Humans; Lymphocyte Depletion; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Remission Induction; T-Lymphocytes; Vidarabine

2020
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:4

    Topics: Adult; Area Under Curve; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2021
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
    Leukemia, 2022, Volume: 36, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, Local; Prognosis; Rituximab; Survival Rate; Telomere Homeostasis; Tumor Suppressor Protein p53; Vidarabine

2022
Targeting CD28-CD86 Pathway for Refractory Myeloma Through CTLA4Ig-Based Reduced-Intensity Conditioning and Donor Lymphocyte Infusions After Haploidentical Transplantation.
    Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:8

    Topics: Abatacept; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-2 Antigen; CD28 Antigens; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation

2019
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Leukemia research, 2013, Volume: 37, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2013
Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
    Future oncology (London, England), 2013, Volume: 9, Issue:12

    Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Recurrence, Local; Rituximab; Vidarabine

2013
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2014
Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma.
    European journal of haematology, 2014, Volume: 93, Issue:6

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2014
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
    Hematological oncology, 2015, Volume: 33, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Therapy; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2015
Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.
    American journal of hematology, 2015, Volume: 90, Issue:2

    Topics: Adult; Analysis of Variance; Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Cancer, 2015, Apr-01, Volume: 121, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Young Adult

2015
Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Japan; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2015
Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Hematological oncology, 2017, Volume: 35, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2017
Successful Treatment With Total Skin Electron Beam Therapy in a Child With Isolated Cutaneous Relapsed AML.
    Journal of pediatric hematology/oncology, 2015, Volume: 37, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Electrons; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Skin Diseases; Vidarabine

2015
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:1

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2016
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
    Blood, 2016, Feb-25, Volume: 127, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Separation; Cyclophosphamide; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exome; Humans; Immunoprecipitation; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation, Missense; Neoplasm Recurrence, Local; Ribosomal Proteins; Rituximab; Transfection; Tumor Suppressor Protein p53; Vidarabine

2016
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
    The Lancet. Haematology, 2015, Volume: 2, Issue:10

    Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2015
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
    Prescrire international, 2016, Volume: 25, Issue:170

    Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine

2016
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Feasibility Studies; Female; Haplotypes; Humans; Immunotherapy; Infant; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prognosis; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2010
Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
    Leukemia, 2010, Volume: 24, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunomodulation; Immunotherapy; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Rituximab; Survival Rate; Vidarabine

2010
FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.
    Journal of experimental & clinical cancer research : CR, 2011, Feb-08, Volume: 30

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Feasibility Studies; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radioimmunotherapy; Retrospective Studies; Rituximab; Vidarabine; Yttrium Radioisotopes

2011
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
    Leukemia research, 2011, Volume: 35, Issue:8

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Primary Myelofibrosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2011
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
    Journal of pediatric surgery, 2011, Volume: 46, Issue:11

    Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine

2011
FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
    Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Salvage Therapy; Survival Rate; Vidarabine

2012
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
    The pharmacogenomics journal, 2013, Volume: 13, Issue:4

    Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Enzymes; Female; Gemtuzumab; Genetic Heterogeneity; Genotype; Humans; Idarubicin; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine

2013
Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma.
    American journal of hematology, 2012, Volume: 87, Issue:9

    Topics: Adult; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2012
The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
    Leukemia, 2013, Volume: 27, Issue:2

    Topics: Antineoplastic Agents; Biological Assay; Drug Monitoring; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Patient Selection; Predictive Value of Tests; Prognosis; Random Allocation; Randomized Controlled Trials as Topic; Survival Rate; Vidarabine

2013
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
    Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13

    Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Cladribine; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Vidarabine

2002
Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
    Leukemia, 2003, Volume: 17, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine

2003
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-01, Volume: 9, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Complement Membrane Attack Complex; Complement System Proteins; Cysteine Endopeptidases; Cytochromes c; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Enzyme Activation; Glucocorticoids; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Multienzyme Complexes; Neoplasm Recurrence, Local; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Tumor Cells, Cultured; Vidarabine; X-Linked Inhibitor of Apoptosis Protein

2003
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
    Annals of hematology, 2004, Volume: 83, Issue:4

    Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine

2004
BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
    Leukemia, 2004, Volume: 18, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporine; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Hematopoietic System; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mycophenolic Acid; Neoplasm Recurrence, Local; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2004
High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    The Korean journal of internal medicine, 2004, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2004
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Vidarabine; Whole-Body Irradiation

2005
Five-month marrow aplasia in a child with refractory acute myeloid leukemia: successful management with continuous granulocyte support and reduced-intensity conditioning followed by matched unrelated bone marrow transplantation.
    Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:4

    Topics: Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Female; Graft vs Host Disease; Granulocytes; Humans; Leukemia, Myelomonocytic, Acute; Melphalan; Neoplasm Recurrence, Local; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2005
Pulmonary lymphoma of the mucosa-associated lymphoid tissue type: Report of a case with cytological, histological, immunophenotypical correlation, and review of the literature.
    Annals of diagnostic pathology, 2005, Volume: 9, Issue:3

    Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Humans; Immunophenotyping; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Treatment Outcome; Vidarabine; Vincristine

2005
Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome; Vidarabine

2005
Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
    Pediatric blood & cancer, 2006, May-01, Volume: 46, Issue:5

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Cyclosporine; Fanconi Anemia; Female; Fetal Blood; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methylprednisolone; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Survival Rate; T-Lymphocytes; Treatment Outcome; Vidarabine

2006
[Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2005, Aug-18, Volume: 37, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Teniposide; Treatment Outcome; Vidarabine

2005
[Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Dexamethasone; Doxorubicin; Female; Hemoglobins; Humans; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Myeloma Proteins; Neoplasm Recurrence, Local; Remission Induction; Vidarabine; Vincristine

2005
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:9

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Thrombocytopenia; Vidarabine

2007
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
    Leukemia, 2008, Volume: 22, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Steroid-responsive interstitial pneumonitis after fludarabine therapy.
    Chest, 1997, Volume: 111, Issue:5

    Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Cough; Fatal Outcome; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Interstitial; Male; Neoplasm Recurrence, Local; Prednisolone; Prednisone; Respiratory Distress Syndrome; Respiratory Insufficiency; Vidarabine

1997
Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes.
    Leukemia, 2000, Volume: 14, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunologic Factors; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Vidarabine

2000
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Bone marrow transplantation, 2000, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Life Tables; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2000
Analysis of recurrent failure times data: should the baseline hazard be stratified?
    Statistics in medicine, 2001, Dec-30, Volume: 20, Issue:24

    Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Proportional Hazards Models; Randomized Controlled Trials as Topic; Rhinitis; Treatment Failure; Vidarabine

2001
Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues.
    American journal of hematology, 2002, Volume: 70, Issue:1

    Topics: 2-Chloroadenosine; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Immunosuppressive Agents; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nucleosides; Vidarabine

2002